Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Manufacturing Safety Bill Resurfaces Without Inspection Fees

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's foreign and domestic oversight powers would increase under the legislation, which has been stripped down in an apparent effort to speed passage.

You may also be interested in...



GMP Third-Party Audits Offered In Draft Senate User Fee Legislation

Bipartisan group of senators unveils several draft provisions of user fee legislation, including a program to allow third-party auditors to evaluate manufacturing facility compliance with U.S. standards for drugs.

USP To Bring Global Perspective To Track And Trace Discussion

The U.S. Pharmacopeial Convention released a framework Jan. 4 for instituting supply chain security measures and plans a May workshop with speakers from other countries to discuss their programs for tracking drug components and products through distribution channels.

USP To Bring Global Perspective To Track And Trace Discussion

The U.S. Pharmacopeial Convention released a framework Jan. 4 for instituting supply chain security measures and plans a May workshop with speakers from other countries to discuss their programs for tracking drug components and products through distribution channels.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS071105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel